Hallmarks of *Alpha-* and *Betacoronavirus* non-structural protein 7+8 complexes

Boris Krichel[1], Ganesh Bylapudi[2], Christina Schmidt[3], Clement Blanchet[4], Robin Schubert[3], Lea Brings[3], Martin Koehler[5], Renato Zenobi[5], Dmitri Svergun[4,] Kristina Lorenzen[3], Ramakanth Madhugiri[2], John Ziebuhr[2], Charlotte Uetrecht[1,3]*

[1]Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany;

[2] Institute of Medical Virology, Justus Liebig University Giessen, Giessen, Germany;

[3]European XFEL GmbH, Schenefeld, Germany;

[4]EMBL Hamburg c/o DESY, Notkestraße 85, 22607 Hamburg, Germany

[5]ETH Zurich D-CHAB Lab of Organic Chemistry, Zürich, Switzerland;

*correspondence to charlotte.uetrecht@xfel.eu

Abstract

Coronaviruses infect many different species including humans. The last two decades have seen three zoonotic coronaviruses with SARS-CoV-2 causing a pandemic in 2020. Coronaviral non-structural proteins (nsp) built up the replication-transcription complex (RTC). Nsp7 and nsp8 interact with and regulate the RNA-dependent RNA-polymerase and other enzymes in the RTC. However, the structural plasticity of nsp7+8 complex has been under debate. Here, we present the framework of nsp7+8 complex stoichiometry and topology based on a native mass spectrometry and complementary biophysical techniques of nsp7+8 complexes from seven coronaviruses in the genera *Alpha-* and *Betacoronavirus* including SARS-CoV-2. Their complexes cluster into three groups, which systematically form either heterotrimers or heterotetramers or both, exhibiting distinct topologies. Moreover, even at high protein concentrations mainly heterotetramers are observed for SARS-CoV-2

nsp7+8. From these results, the different assembly paths can be pinpointed to specific

residues and an assembly model is proposed.

Introduction

Seven coronaviruses (CoV) from six coronavirus species are known to cause infections in

humans. While four of these viruses (HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1)

predominantly cause seasonal outbreaks of (upper) respiratory tract infections with mild

disease symptoms in most cases, three other coronaviruses (SARS-CoV, MERS-CoV and

SARS-CoV-2) of recent zoonotic origin are associated with lower respiratory tract disease

including acute respiratory distress syndrome (ARDS) [1-3]. SARS-CoV-2 is the etiologic

agent of COVID-19, a respiratory disease with a wide spectrum of clinical presentations and

outcomes. First detected in December 2019, it quickly became pandemic with numbers still

growing (>30 million confirmed cases, >1,000,000 deaths, by end September 2020) [4-6].

COVID-19 caused major perturbations of historical dimensions in politics, economics and

healthcare. Moreover, coronaviruses are important, widespread animal pathogens as

illustrated by feline intestine peritonitis virus (FIPV) causing a severe and often fatal disease

in cats [7] or porcine coronaviruses [8], such as transmissible-gastroenteritis virus (TGEV) or

porcine epidemic diarrhea virus (PEDV), the latter causing massive outbreaks and economic

losses in swine industry.

The viral replication machinery is largely conserved across the different coronavirus species

from the four currently recognized genera *Alpha-*, *Beta-*, *Gamma-* and *Deltacoronavirus*

*(*subfamily *Orthocoronavirinae*, family *Coronaviridae*) [9]. The key components are generally

referred to as nonstructural proteins (nsp) and encoded by the viral replicase genes (ORFs 1a

and 1b) and translated as parts of the replicase polyproteins pp1a (nsp1-11) or pp1ab (nsp1-

16). Translation of the ORF1b-encoded C-terminal part of pp1ab requires a ribosomal (-1)-

frameshift immediately upstream of the ORF1a stop codon. Two proteases called PL_{pro} (one

or two protease domains in nsp3) and M_{pro} (also called $3CL_{pro}$ or nsp5) facilitate polyprotein

processing into 16 (sometimes 15) mature nsps. The majority of these nsps form a membrane-

anchored, highly dynamic protein-RNA machinery, the replication-transcription complex

(RTC), which mediates replication of the ~30 kb single-strand (+)-sense RNA genome and

production of subgenomic mRNAs [9, 10].

The main CoV-RTC building block is the fastest known RNA-dependent RNA-polymerase (RdRp) residing in the nsp12 C-terminal domain [11]. For RdRp activity, nsp12 requires binding to its cofactors nsp7 and nsp8 [12]. Recently, high-resolution structures illuminated two binding sites at nsp12, the first for an nsp7+8 (1:1) heterodimer and the second for a single nsp8 [13-16]. For *in vitro* RdRp activity assays, different methods were used to assemble the polymerase complex [11, 17, 18]. So far, the highest processivity *in vitro* was obtained by mixing nsp12 with a flexibly linked nsp7L8 fusion protein.

Recently, we reported that SARS-CoV nsp7 and nsp8 form a heterotetramer (2:2) in solution, in which nsp7 subunits have no self-interaction and rather sandwich an nsp8 scaffold with putative head-to-tail interactions [19]. Current knowledge of full-length nsp7+8 complexes is mainly based on two X-ray crystal structures, each of which displays a different quaternary conformation. First, a SARS-CoV nsp7+8 (8:8) hexadecamer is assembled from four (2:2) heterotetramers with similar topologies but two distinct conformations, T1 and T2, which are both consistent with our in solution structure [19] [20]. Second, in a feline coronavirus (FIPV) nsp7+8 (2:1) heterotrimer, nsp8 is associated to two nsp7 molecules that self-interact [21]. Moreover, structures of SARS-CoV and SARS-CoV-2 with *N*-terminally truncated forms of nsp8, thus lacking the self-interaction domain, revealed heterotetrameric nsp7+8 complexes around an nsp7 scaffold [22, 23].

Current knowledge of coronavirus nsp7+8 complexes suggests a remarkable architectural plasticity but is unsupportive of deducing common principles of complex formation. Moreover, it is unknown if the quaternary structure of nsp7+8 is conserved within a given coronavirus species or between genera. To fill these knowledge gaps, we analyzed nsp7+8 complexes derived from seven viruses of the *Alpha-* and *Betacoronavirus* genera, including a range of human coronaviruses, namely SARS-CoV, SARS-CoV-2, MERS-CoV and HCoV-229E (Table S 2). We used native mass spectrometry (MS) to illustrate the landscape of nsp7+8 complexes *in vacuo*, collision induced dissociation tandem MS (CID-MS/MS) to reconstruct complex topology and complementary methods to verify the results [24, 25]. Our findings reveal distinct sets of nsp7+8 complexes for the different CoV species. The results hint at the properties that lead to complex heterogeneity and suggest common principles of complex formation based on two conserved binding sites.

Experimental Results

Native MS illustrates the landscape of nsp7+8 complexes.

Figure 1: Three complexation groups formed by CoV nsp7+8. Representative mass spectra showing distinct nsp7+8 complexation patterns that were classified into the three groups A, B and AB. Complex formation triggered by M^{pro} (M) mediated cleavage of 15 µM CoV nsp7-8-His$_6$ or MERS-CoV nsp7-11-His$_6$ precursors in 300 mM ammonium acetate (AmAc), 1 mM DTT, pH 8.0. (**A**) SARS-CoV-2 representing group A forms heterotetramers (nsp7+8 (2:2), red), (**B**) FIPV from group B forms heterotrimers (nsp7+8 (2:1), blue) and (**C**) HCoV-229E from group AB forms both complex stoichiometries (2:2 and 2:1). (**D**) In case of MERS-CoV, also group AB, cleavage of the longer nsp7-11-His$_6$ precursor resulted in additional processing intermediates (labeled A, B, C). In all three complexation groups, nsp7+8 (1:1) heterodimeric intermediates are observed (green). For spectra of all seven CoV nsp7+8 complexes see Figure S 2.

To ensure authentic nsp7 and nsp8 N- and C-termini, which allow for optimal nsp7+nsp8 complex assembly, the proteins are expressed as nsp7-8-His$_6$ polyprotein precursors and cleaved by their cognate protease M^{pro} (Figure S 1). Native MS provides an overview of mass

species in solution, while CID-MS/MS confirms the stoichiometry of protein complexes.

Distinct oligomerization patterns of nsp7+8 (1:1) heterodimers, (2:1) heterotrimers and (2:2)

heterotetramers in the different CoV allowed us to categorize their nsp7+8 complexes into

three groups (Figure 1, Figure S 2). SARS-CoV and SARS-CoV-2 (species *Severe acute*

respiratory syndrome-related coronavirus, genus *Betacoronavirus*) represent nsp7+8 group A

complex formation pattern (Figure 1 A). Consistent with our previous work, SARS-CoV

nsp7+8 complexes exist primarily as a heterotetramer comprising two copies of each nsp7

and nsp8 (2:2) [19]. Expectedly, SARS-CoV-2 nsp7+8 form identical (2:2) complexes given the

high sequence identity of 97.5 % in the nsp7-8 region (Table S 2). Next, relative peak

intensities in native MS of nsp7+8 complexes are converted in a semi-quantitative analysis

into abundances of complex species [26]. The heterodimer (2-4 %) is much less abundant

than the heterotetramer (96-98 %) suggesting high affinity and hence efficient conversion of

heterodimeric intermediates into heterotetramers. Hence, group A only forms two types of

nsp7+8 complexes, heterodimers (1:1) and -tetramers (2:2), with the latter clearly being

predominant.

In FIPV and TGEV from the species *Alphacoronavirus 1*, genus *Alphacoronaviru*s, nsp7 and

nsp8 proteins share a sequence identity of 93.9% (Table S 2). Their nsp7+8 complexes are

assigned to group B forming predominantly nsp7+8 (2:1) heterotrimers (83 %) and to a lesser

extent heterodimers (1:1) (~17 %) (Figure 1 B). An nsp7+8 (2:1) heterotrimeric structure has

previously been reported for FIPV but not for TGEV or any other CoV. The association of a

single nsp8 with two nsp7 indicates that group B nsp7+8 complexes lack the ability to form

tetramers around an nsp8 scaffold.

The third oligomerization pattern is observed for nsp7+8 of HCoV-229E and PEDV, which

represent different species in the genus *Alphacoronavirus.* They share only 70.9 % sequence

identity in the nsp7-8 region and even less (42-62 %) with the other CoV species examined

(Table S 2). PEDV and HCoV-229E nsp7+8 form three major types of oligomers with slightly

different efficiencies: heterodimers (1:1), heterotrimers (2:1) and heterotetramers (2:2)

(HCoV-229E: 20 %, 12 % and 69 %; PEDV: 52 %, 6 % and 42 %, respectively) (Figure 1 C). By

forming both, heterotrimers and -tetramers, these complexes combine properties described

above for groups A and B, and are hence categorized into a separate group named

accordingly AB. This begs the question whether assembly pathways and structures of

heterotetramers in group A and AB are similar. Either, two heterodimers form a

heterotetramer around an nsp8 scaffold as in group A [19] or alternatively the heterotrimer

recruits another nsp8 subunit to the complex, thus employing an nsp7 core [21]. The latter

pathway has recently been reported for SARS-CoV-2 nsp7+8 heterotetramers containing *N*-

terminally truncated nsp8 [23].

Additionally, nsp7+8 complexation after M^{pro} mediated cleavage of a MERS-CoV nsp7-11-

His$_6$ precursor is compared (Figure 1 D). This larger precursor, comprising nsp7, nsp8, nsp9

nsp10 and nsp11, behaves similar to nsp7-9-His$_6$ (Figure S1) and is used because initial

attempts to cleave nsp7-8 only constructs failed. Proteolytic processing of this polyprotein

precursor leads to cleavage intermediates (Figure 1 D). Such processing intermediates have

been proposed to occur intracellularly and to function distinctly from the individual nsps in

e.g. regulation of RTC assembly and viral RNA synthesis [27]. Here, signal intensities of

these intermediates provide insights into the processing sequence. Surprisingly, the

dominant intermediate is nsp10-11-His$_6$, despite the small size of nsp11 and a hence expected

high accessibility of the nsp10/11 cleavage site. Therefore, slow cleavage and prolonged

presence of an nsp10-11 intermediate may have functional implications warranting further

studies. Notably, in many CoV polyproteins the nsp10/11 and/or nsp10/12 cleavage sites

contain replacements (Pro in MERS-CoV) of the canonical P2 Leu residue conserved

throughout most M^{pro} cleavage sites, suggesting that slow or incomplete cleavage is

beneficial for these particular sites. Moreover, this cleavage site has different *C*-terminal

contexts in the two CoV replicase polyproteins, nsp10-11 in pp1a and nsp10-12 in pp1ab.

While the structure of the small nsp11 (~1.5 kDa) is unknown, nsp12 is a large folded protein

(~105 kDa), which potentially improves the accessibility of the nsp10/12 site for M^{pro}. Similar

effects have been observed for the nsp8/9 cleavage site, which is efficiently cleaved in the

protein but not in peptide substrates [19, 28]. The question remains if unprocessed nsp10-11

and/or nsp10-12 intermediates exist in virus-infected cells for prolonged times to fulfill

specific functions. Other detected intermediates are nsp7-8-9 and nsp9-10 lacking nsp11-His$_6$.

Particularly, the nsp9-10 intermediate has not been identified in our analysis of SARS-CoV

nsp7-10 processing, suggesting differences in the *in vitro* processing order between SARS-

CoV and MERS-CoV.

MERS-CoV nsp7+8 forms heterodimers (1:1), -trimers (2:1) and -tetramers (2:2) (73 %, 8 %

and 19 %, respectively), thus demonstrating a group AB complexation pattern. However, we

cannot confirm the heterotrimer (2:1) formation by CID-MS/MS due to spectral complexity.

Moreover, because of incomplete cleavage as is evident from the cleavage intermediates, signals assigned to the nsp7+8 heterodimer likely overlap with signals of unprocessed nsp7-8. Thus, complete cleavage of nsp7-8 could shift the peak fractions from heterodimer to heterotrimer or -tetramer.

Homodimerization of subunits and precursors.

In the mass spectra of nsp7+8 complexes, monomers and homodimers of nsp7 and nsp8 are also observed. While nsp7 homodimers are identified for all seven CoV species tested, nsp8 homodimers are only detected for SARS-CoV and SARS-CoV-2, which belong to group B forming exclusively nsp7+8 heterotetramers around a dimeric nsp8 scaffold (Figure S 3). Moreover, the oligomeric states of the different uncleaved nsp7-8 precursors are probed. Notably, precursors from group B CoVs are mostly monomeric, whereas precursors from group AB and A CoVs are in varying equilibria between monomers and dimers (Figure S 4). The different oligomerization propensities of precursors suggest that molecular interactions driving dimerization of nsp7-8 precursors could critically affect subsequent nsp7+8 oligomerization. For SARS-CoV and SARS-CoV-2, the nsp7-8 dimer affinity is low as two-fold dilution to 9 μM shifted the equilibrium towards a monomeric state (Figure S 5). This is in line with our previous findings [19], in which *C*-terminally extended SARS-CoV nsp7-9-His$_6$ and His$_6$-nsp7-10 polyprotein constructs were mainly monomeric, suggesting that the presence of the extra *C*-terminal sequence further destabilizes an already weak dimerization.

Collision-induced dissociation reveals complex topology

Figure 2: Gas-phase dissociation reveals complex topology. CID-MS/MS product ion spectra (**A** and **C**), dissociation pathways and topology maps (**B** and **D**) for HCoV-229E nsp7+8 (2:1) heterotrimers and (2:2) heterotetramers are shown. With increasing collisional voltage protein complexes are successively stripped from their subunits revealing alternative dissociation pathways. The remaining dimeric species expose direct subunit interactions in the nsp7+8 complexes (grey boxes). Charge states are labeled. (**A** and **B**) The heterotetramers (2:2) undergo two consecutive losses resulting in dimeric product ions of nsp7+8 (1:1) and nsp8₂. These products indicate that nsp7:nsp8 and nsp8:nsp8 have direct interfaces in heterotetramers. (**C** and **D**) HCoV-229E heterotrimers dissociate into the dimeric products nsp7+8 (1:1) and nsp7₂ indicating direct interfaces between nsp7:nsp8 and nsp7:nsp7 in heterotrimers. All CoV heterotrimers follow similar dissociation pathways, also all CoV heterotetramers follow a common dissociation route, which allow a topological reconstruction of two distinct complex architectures (Figure S 6-Figure S 10).

To deduce the complex topology in the different groups of nsp7+8 interaction patterns, we applied CID-MS/MS using successive subunit dissociations to dissect conserved interactions. CID-MS/MS of the HCoV-229E nsp7+8 heterotetramer (2:2) reveals two dissociation pathways, in which first one nsp7 subunit is ejected from the complex followed by another nsp7 or an nsp8 subunit. After two consecutive losses, the product ions are nsp7+8 (1:1) and

nsp8$_2$ dimers, providing evidence for specific subunit interfaces in the complex (Figure 2 A).

From these results, the complex topology is deduced as a heterotetramer based on an nsp8$_2$

dimer scaffold, in which each nsp8 binds only one nsp7 subunit. Strikingly, this is identical

to our previously reported SARS-CoV nsp7+8 heterotetramer (2:2) architecture [19]. In fact,

all nsp7+8 (2:2) heterotetramers of groups A and AB (SARS-CoV-2, SARS-CoV, PEDV,

HCoV-229E and MERS-CoV) resulted in similar dissociation pathways, subunit interfaces

and topology maps, suggesting that these structures are similar across these diverse CoVs.

Next, the dissociation pathway of the HCoV-229E nsp7+8 (2:1) heterotrimers is monitored in

CID-MS/MS (Figure 2 B). After ejection of one nsp7 or nsp8 subunit, product dimers of

nsp7+8 (1:1) and nsp7$_2$ are detected, indicating specific subunit interfaces between nsp7:nsp8

and nsp7:nsp7. Again, similar dissociation pathways and subunit interfaces are found for

group B and AB heterotrimers (FIPV, TGEV, HCoV-229E and PEDV). Topological

reconstructions reveal a heterotrimer forming a tripartite interaction between one nsp8 and

two nsp7 subunits. These results agree with the reported X-ray structure of FIPV nsp7+8 [21]

and indicate that heterotrimers of these CoVs species have similar arrangements. In turn, this

implies that heterotrimers and heterotetramers follow distinct assembly paths.

Chemical cross-linking confirms the formation of specific complexes.

To further support the native MS results, which relies on spraying from volatile salt solutions

(e.g. ammonium acetate, AmAc), complementary methods compatible with conventional

buffers supplemented with sodium chloride are applied. To provide additional evidence for

specific nsp7+8 complex formation, the FIPV and HCoV-229E nsp7+8 complexes are

stabilized via crosslinking with glutaraldehyde and subjected to XL-MALDI MS (Cross-

linking Matrix-assisted laser ionization MS) (Figure S 11). Peak areas in the MALDI mass

spectra are assigned to FIPV nsp7+8 heterodimer, heterotrimer and –tetramer (8.5 %, 9.5 %

and 4.2 %, respectively), and HCoV-229E nsp7+8 heterodimer, heterotrimer and –tetramer

(6.7 %, 5.3 % and 6.0 %, respectively). The results suggest a higher abundance of nsp7+8

heterodimer and -trimer complexes in FIPV than in HCoV-229E, while HCoV-229E contains

more heterotetramers. This largely agrees with the results from native MS. However, the

MALDI mass spectra show high background of virtually all possible nsp7+8 stoichiometries

(<200,000 m/z), probably due to over-crosslinking with the rather unspecific glutaraldehyde.

To refine these results, nsp7+8 complexes are stabilized with the amine specific crosslinker

BS[3] and analyzed by SDS-PAGE (Figure S 12). Multiple stoichiometries are identified with a

few prominent bands highlighting the main complexes generated. These bands are assigned

to SARS-CoV nsp7+8 heterodimers and -tetramers, FIPV nsp7+8 heterodimers and -trimers

and HCoV-22E nsp7+8 heterodimers, heterotrimers and -tetramers of HCoV-229E, providing

additional support for the classification of nsp7+8 complexes into groups A (SARS-CoV), B

(FIPV) and AB (HCoV-229E).

Light scattering provides insights into complexation at high protein concentrations

Figure 3: DLS and SAXS reveal oligomeric state of SARS-CoV-2 nsp7+8 at higher protein concentrations. At increasing protein concentrations, the hydrodynamic radius (R_0) remains stable but becomes more homogenous in DLS. (**A**) shows two exemplary DLS plots (1 mg/ml; 15 mg/ml) and (**B**) how the radius R_0 develops with increasing protein concentration. Theoretical hydrodynamic radii ($R_{0,theo}$) of heterotetramer and hexadecamer candidate structures are indicated (red dashed lines). (**C**) displays SAXS curves collected at different solute concentrations and (**D**) the fit of the curve computed from T1 tetramer (red line) to the SAXS data collected at 1.2 mg/mL (blue dots with error bars). (**E**) Radius of gyration (R_g) and (**F**) molecular weight estimated from the SAXS data both stabilize with increasing concentration like in DLS on values that are in agreement with the $R_{0,theo}$ of the T1 nsp7+8 (2:2) heterotetramer.

To test the stoichiometry at higher protein concentrations in solution, dynamic light scattering (DLS) of SARS-CoV-2 nsp7+8 from 1 to 15 mg/mL is performed (Figure 4 A). No significant increase of the hydrodynamic radius (R_0) occurrs with increasing concentration. At the same time, the measured radii become more stable and fluctuate less, which suggests a shift towards higher complex homogeneity and a reduced fraction of free nsp7 and nsp8.

For SARS-CoV-2, no complex structure is available for full-length nsp7+8 proteins but, previously, a SARS-CoV nsp7+8 (8:8) has been reported using X-ray crystallography [20], where high protein concentrations are deployed. In order to relate the average experimental hydrodynamic radius ($R_{0,exp} = 4.25 \pm 0.61$ nm) to candidate structures, the theoretical hydrodynamic radius is calculated for the SARS-CoV nsp7+8 (8:8) hexadecamer ($R_{0,theo} = 5.80 \pm 0.29$ nm) and a subcomplex thereof, a putative nsp7+8 heterotetramer (2:2) in T1 conformation ($R_{0,theo} = 4.52 \pm 0.27$ nm) (Figure S 13). This is the only model with full-length nsp8 that agrees with the stoichiometry and topology determined by native MS. At physiologically relevant concentrations from 1 to 10 mg/mL, the average experimental hydrodynamic radius agrees well with the theoretical hydrodynamic radius of the heterotetramer T1. Hence a heterotetramer is likely the prevailing species in solution (Figure 4 B).

To underpin the DLS results, SAXS data are collected on solutions of nsp7+8 at concentrations ranging from 1.2 to 47.7 mg/ml. The normalized SAXS intensities increase at low angles with increasing concentration (Figure 4 B and Table S 3), suggesting a change in the oligomeric equilibrium and a formation of larger oligomers. This trend is well illustrated by the evolution of the apparent radius of gyration and molecular weight of the solute determined from the SAXS data (Figure 4 E and F). The increase in the effective molecular weight, from about 50 to 80 kDa suggests that the change in oligomeric state is limited and that the tetrameric state (MW_{theo}: 62 kDa) remains predominant in solution.

The SAXS data at low concentrations (<4 mg/mL) fit well the computed scattering from heterotetramer T1 but misfits appear at higher concentration (Figure 4 D, structure of T1 shown in Figure S 13and the discrepancy χ^2 reported in Table S 4). Mixtures of heterotetramers and hexadecamers cannot successfully fitted to the higher concentration data either (Figure S 14). To further explore the oligomeric states of nsp7+8, a dimer of T1 is used to simultaneously fit the curves collected at different concentrations by a mixture of

heterotetramers and -octamers. Reasonable fits to all SAXS data are obtained with volume fractions of heterooctamers growing from 0 to 0.52 with increasing concentration (Figure S 14). Based on the flexibility of the molecule and the multiple possible binding sites between nsp7 and nsp8, it is not surprising that larger assemblies are observed at very high solute concentrations. The SAXS and DLS results provide evidence that the nsp7+8 (2:2) heterotetramer is the prevailing stoichiometry in solution at physiological concentrations (1-10 mg/mL with volume fractions between 1 and 0.7).

Potential implications of sequence conservation on heterotrimer and -tetramer formation.

To extend this analysis, we select candidate structures in agreement with the stoichiometry and topology observed (Figure S 10). For the heterotetramer, two conformers of nsp7+8 (2:2) subcomplexes, T1 and T2, of correct architecture can be extracted from the larger SARS-CoV nsp7+8 hexadecamer [20] (pdb 2ahm), (Figure S 13 A). Both conformers constitute a head to tail interaction of two nsp7+8 heterodimers mediated by an nsp8-nsp8 interface. Notably, nsp8 in T1 is more extended, revealing an almost full-length amino acid sequence (2-193), while in T2 the nsp8 *N*-terminal 35 to 55 residues are unresolved. For the heterotrimeric complexes, the only deposited structure is the FIPV nsp7+8 (2:1) heterotrimer [21] (pdb 3ub0), which agrees well with our experimental topology (Figure S 13 B).

In order to identify molecular determinants for heterotrimer or -tetramer formation, the candidate structures are examined for molecular contacts (van der Waals radius -0.4 Å). The conservation of contact residues is evaluated in a sequence alignment to identify possible determinants of different stoichiometries (Figure S 15). Notably, most amino acids lining subunit interfaces in heterodimers, -trimers and -tetramers are conserved. The interfaces in the candidate structures occupy two common structural portions of the nsp8 subunit (Figure 4 A). The first binding site (BS I) is located between the nsp8 head and shaft domain, responsible for binding of nsp7 (I) in heterodimer formation, as seen in all available high resolution structures of nsp7+8 [20-23] and the polymerase complex [13-16]. The second binding site (BS II) appears highly variable in terms of its binding partner and lies at the nsp8 elongated *N*-terminus. In fact, one largely conserved motif (res60-70) is responsible for the main contacts in the entire candidate complexes selected based on our data: nsp7+8 (2:2) T1 and T2 for the heterotetramer and nsp7+8 (2:1) for the heterotrimer. The respective sidechains take positions on one side of the nsp8 α-helix and have the ability to form

interactions with either mainly nsp7 (partly nsp8) in the SARS-CoV nsp7+8 (2:2) heterotetramer T1, mainly nsp8 (partly nsp7) in the SARS-CoV nsp7+8 heterotetramer T2 or only nsp7 in the FIPV nsp7+8 (2:1) heterotrimer (Figure S 16 A-C). Due to its sequence conservation, it is unlikely that alone this motif at BS II has a decisive impact for heterotrimer or -tetramer formation.

Figure 4: Candidate structures and sequence conservation of nsp7+8 heterotrimers and -tetramers. Candidate structures for nsp7+8 heterotetramer and –trimer are chosen based on experimental stoichiometry and topology

Therefore, unique interactions could exist, which explain the shift in complex stoichiometry

from heterotrimer to -tetramer observed in the different CoVs categorized into group A, AB

and B (Figure 4 B). Here, we identify a possibly heterotetramer stabilizing contact site in T2,

where nsp8 Glu77 self-interacts with nsp8II Glu77, which gives the complex density and

compactness (Figure 4 C). This residue is only present in nsp8 of SARS-CoV and SARS-CoV-

2 from group A and MERS-CoV of group AB. However, homology models suggest that in

the other tetramer forming complexes of group AB, HCoV-229E and PEDV, nsp8 Asn78

could partially replace this interaction (Figure 4 D). This is different in group B viruses,

forming only heterotrimers, where residues at these positions are nsp8 Val77 and Asp78,

with the Asp78 possibly being solvent exposed and hence unable to replace this interaction.

Furthermore, we also identify a contact site possibly stabilizing the heterotrimer in the

crystal structure of the FIPV nsp7+8 (2:1), which reveals that a second subunit of nsp7

(nsp7II) is locked via Phe76 to nsp8 (Figure 4 E). Importantly, this residue is uniquely

conserved among trimer forming complexes of group B and group AB, but replaced by nsp7

Leu76 in the strictly heterotetramer forming group A.

These findings are compared to the recently released structure of the polymerase complex

(pdb 6xez, Figure S 16 D and E), comprising nsp7+8+12+13(1:2:1:2) [29]. The residues

potentially responsible for a shift in quaternary structure, nsp8 Glu77 or Asp78 and nsp7

Phe76, are distant from any protein-protein or protein-RNA interaction and thus are not

expected to play a role in polymerase complex formation. Surprisingly, the identical set of

residues in BS II supports all interactions (Glu60, Met62, Ala63, Met67 and Met70) between

nsp8b and nsp12/nsp13.1 and between nsp8a and nsp13b (Figure S 16 D and E). Notably,

within the polymerase complex amino acids involved in RNA binding point in the opposite

direction of the protein interfaces and have little or no role in nsp7+8 complex formation.

Discussion

Our findings reveal the nsp7+8 quaternary composition of seven CoVs representing five coronavirus species of the genera *Alpha-* and *Betacoronavirus*. Viruses of the same species (SARS-CoV/SARS-CoV-2 and TGEV/FIPV, respectively) produce the same type of nsp7+8 complexes. Next to a conserved nsp7+8 heterodimer (1:1), the inherent specificity of nsp7+8 complex formation categorizes them into three groups: group A forming only heterotetramers (2:2), group B forming only heterotrimers (2:1) and group AB forming both heterotetramers (2:2) and heterotrimers (2:1). Complexes of the same stoichiometry exhibit a conserved topology, consisting of an nsp8 homodimeric scaffold for the heterotetramers and an nsp7 homodimeric core for the trimers. Candidate structures based on our results highlight *Alpha-* and *Betacoronavirus*-wide conserved binding sites on nsp8, named BS I and BS II, which provide the modular framework for a variety of complexes. Furthermore, unique molecular contacts for the complex groups have the potential to determine the ability and preference for heterotrimer and/or heterotetramer formation.

We provide evidence that, even at high concentrations, the SARS-CoV-2 nsp7+8 heterotetramer (2:2) represents the predominant species. In order to relate our results to *in vivo* conditions, we consider the following aspects: According to maximum molecular crowding [30], polyproteins pp1a and pp1ab can reach a maximum of 125-450 µM, which translates to 3.9-11.7 mg/mL nsp7+8. This range is covered by our DLS and SAXS analysis. In absence of other interaction partners, we expect that, *in vivo*, the nsp7+8 (2:2) heterotetramer represents the predominant nsp7+8 complex of SARS-CoV-2 and other heterotetramer forming CoVs of complexation groups A and AB.

The heterotetramer candidate structures and models presented here are based on the conformers T1 or T2 of the SARS-CoV heterohexadecamer structure, which contains full-length nsp8 [20]. Although, our results cannot clarify, if one of these conformers is the biologically relevant structure existing in solution, the combined evidence provided here strongly suggests structural similarity to T1/T2. Considering the crystallographic origin of T1/T2 and the overlap of binding sites, the heterotetramer could well be a flexible and dynamic structure in solution.

In contrast to our findings, a SARS-CoV nsp7+8 hexadecamer structure has been reported [20]. However, this structure has been derived from X-ray crystallography, hence showing a

static, frozen state, where the crystal lattice formation favors stabilized arrangements that could differ from the solution state of the protein complexes. In the case of nsp8, the flexible *N*-terminus could inhibit crystal formation, and has been removed in some studies [22, 23]. Alternatively, it may stabilize specific interactions, thereby promoting crystal formation by binding to one of the multiple interfaces presented between nsp7 and nsp8, resulting in a physiologically irrelevant larger oligomeric structure. The SAXS data presented here partially supports this scenario at high protein concentrations but also confirms a predominantly heterotetrameric assembly in solution. Thus, a potential shift of quaternary structure from heterotetramer towards a higher-order complex, such as a heterohexadecamer appears unlikely unless triggered e.g. by binding to nucleic acids as has been repeatedly described for nsp7+8 complexes [20].

All seven CoV nsp7 and nsp8 proteins shown here also form heterodimers (1:1). Such heterodimeric subcomplexes with nsp7 bound to nsp8 BS I have been observed in all deposited complex structures containing nsp7+8 [20-23] or nsp12 [13-16]. Therefore, the heterodimer represents the most basic form of nsp7+8 complexes and likely serves as universal substructure building block in the coordinated assembly of functional RTCs of CoVs from the genera *Alpha-* and *Betacoronavirus*. Moreover, heterotrimer and -tetramer formation are based on a second canonical binding site at the nsp8 *N*-terminal domain, BS II. This site appears to have a high propensity to form complexes with various binding partners (e.g. nsp7+8, nsp12 or nsp13). Accordingly, our analysis suggests that the nsp8 BS II strives for occupation. The nsp7+8 quaternary composition, topology and analysis of binding sites presented here allow us to reconstruct and propose a model of the complex formation pathway (Figure 5).

The preference for heterotrimer and -tetramer can probably be pinpointed to just a few amino acids within nsp8 BS II or interacting with it. Here, we identify two contacts that could have unique discriminatory potential for promoting heterotrimeric (nsp7 Phe76) or heterotetrameric (nsp8 Glu77 and Asn78) quaternary structures. Notably in presence of nsp7 Phe76 and nsp8 Asn78, as observed for group AB, the heterotetramer is always more abundant than the heterotrimer. However, compared to the entire BS II, theses contacts only represent a small share of the binding interface and contribute little interaction energy through van der Waals forces. Nevertheless, the unique position of their contacts could critically determine the types of interactions with one or another binding partner.

Figure 5: Proposed model for nsp7+8 complex formation. (**A**) For complexes of group A, heterodimers form via nsp8 BS I, which quickly dimerize via BS II into a heterotetramer. A theoretic route via a preformed nsp8 scaffold is unlikely to play a role in heterotetramer formation since no nsp7+8 (1:2) intermediates are observed for complexes of SARS-CoV or SARS-CoV-2. Moreover,, nsp7 and nsp8 occupy neighboring positions in the replicase polyproteins, thus favoring their interaction (*in cis*) at early stages in the infection cycle (when intracellular viral polyprotein concentrations are low) over intermolecular interactions between different replicase polyprotein molecules as is also evident from the low dimerization ability of the precursors. (**B**) For group B complexes, we propose the formation of a heterodimer intermediate via nsp8 BS I or BS II and subsequent recruitment of a second nsp7, resulting an nsp7+8 (2:1) heterotrimer. This is also supported by the relatively high peak fractions of heterodimers detected. Group AB complexes can use both complexation pathways. In line with this, the proteins also produce a relatively high heterodimer signal but, ultimately, prefer to form heterotetramers rather than heterotrimers.

Since the critical residues required for nsp7+8 complex formation have no overlap with nsp12 interaction sites, direct docking of preformed heterotrimers and -tetramers to nsp12 can be expected. Furthermore, heterotrimeric and -tetrameric structures are compatible with accommodation of specific RNA structures similar to what has been suggested for heterohexadecameric nsp7+8 by Rao et al. [14]. Notably, if heterotrimeric or -tetrameric nsp7+8 structures were associated with nsp12, the binding site for nsp13 would be blocked, which may have regulatory implications for CoV replication. Altogether, these conserved binding mechanisms and overlapping binding sites confirm the proposed role of nsp8 as a major interaction hub within the CoV RTC [31], and indicate critical regulatory functions by specific nsp7+8 complexes.

Finally, we can only speculate about possible reasons for the existence of different nsp7+8

complexes: (1) Similar kinetic stability due to occupation of both binding sites (both

structures exist because they are equally efficient in occupying BS I and BS II), (2) unknown

functional relevance in CoV replication (e.g. specificity to RNA structures channeled to the

nsp12 RdRp) or (3) adaption to host factors and possible regulatory functions.

In summary, our work shows, and provides a framework to understand, the characteristic

distribution and structures of nsp7+8 (1:1) heterodimer, (2:1) heterotrimers and (2:2)

heterotetramers in representative alpha- and betacoronaviruses. The nsp7+8 structure in

solution can be used to investigate its independent functional role in the formation of active

polymerase complexes and, possibly, regulation and coordination of polymerase and other

RTC activities, for example in the context of antiviral drug development targeting different

subunits of CoV polymerase complexes reconstituted *in vitro*.

Material and Methods

Cloning and gene constructs

The codon optimized sequence for the SARS-CoV-2 nsp7-8 region (NC_045512.2) was

synthesized by Eurofins scientific SE with overhangs suitable for insertion into pASK-

IBA33plus plasmid DNA (IBA Life Sciences). A golden gate assembly approach using Eco31I

(BsaI) (Thermo Fisher Scientific) was used to shuttle the gene into the plasmid. Linker and

tag of the expression construct SARS-CoV-2 nsp7-8-His$_6$ contained the *C*-terminal amino

acids –SGSGSARGS-His$_6$ (SGSG residues as P1'-P4' of Mpro cleavage site and SARGS-His$_6$

residues as the default linker of pASK vectors). The SARS-CoV nsp7-8 pASK33+ plasmid

generated previously [21, 32] was used for the expression of SARS-CoV nsp7-8-His$_6$

containing the *C*-terminal amino acids –SARGS-His$_6$. The expression plasmid for SARS-CoV

M^{Pro} was generated as described by Xue et al.[33]. To produce nsp7-8-SGSGSARGS-His$_6$

precursor proteins in *Escherichia coli*, the nsp7-8 coding sequences of HCoV-229E (HCoV-

229E; GenBank accession number AF304460), FIPV (FIPV, strain 79/1146; DQ010921), SARS-

CoV (strain Frankfurt-1; AY291315), PEDV (PEDV, strain CV777, NC_003436) and TGEV

(TGEV, strain Purdue; NC_038861) were amplified by reverse transcription-polymerase

chain reaction (RT-PCR) from viral RNA isolated from cells infected with the respective

viruses and inserted into pASK3-Ub-CHis$_6$ using restriction- and ligation-free cloning

methods as described before (Tvarogová et al., 2019). Similarly, the nsp7-9 or nsp7-11 coding

region of MERS-CoV (strain HCoV-EMC; NC_019843), was amplified by RT-PCR from infected cells and inserted into pASK3-Ub-CHis$_6$. The HCoV-229E and FIPV nsp5 coding sequences were cloned into pMAL-c2 plasmid DNA (New England Biolabs) for expression as MBP fusion proteins containing a *C*-terminal His$_6$-tag. Primers used for cloning and mutagenesis are available upon request.

Expression and purification

SARS-CoV M^{Pro} was produced with authentic ends as described in earlier work [33]. To produce the precursors, SARS-CoV and SARS-CoV-2 nsp7-8-His$_6$, BL21 Rosetta2 (Merck Millipore) were transformed, grown in culture flasks to OD$_{600}$ = 0.4-0.6, then induced with 50 µM anhydrotetracycline and continued to grow at 20 °C for 16 h. For pelleting, cultures were centrifuged (6000 × g for 20 min) and cells were frozen at -20 °C. Cell pellets were lysed in 1:5 (*v/v*) buffer B1 (40 mM phosphate buffer, 300 mM NaCl, pH 8.0) with one freeze-thaw cycle, sonicated (micro tip, 70 % power, 6 times on 10 s, off 60 s; Branson digital sonifier SFX 150) and then centrifuged (20,000 × g for 45 min). Proteins were isolated with Ni^{2+}-NTA beads (Thermo Fisher Scientific) in gravity flow columns (BioRad). Proteins were bound to beads equilibrated with 20 column volumes (CV) B1 + 20 mM imidazole, then washed with 20 CV B1 + 20 mM imidazole followed by 10 CV of B1 + 50 mM imidazole. The proteins were eluted in eight fractions of 0.5 CV B1 + 300 mM imidazole. Immediately after elution, fractions were supplemented with 4 mM DTT. Before analysis with native MS, Ni^{2+}-NTA eluted fractions containing the polyprotein were concentrated to 10 mg/mL and further purified over a 10/300 Superdex 200 column (GE healthcare) in 20 mM phosphate buffer, 150 mM NaCl, 4 mM DTT, pH 8.0. The main elution peaks contained nsp7-8. For quality analysis, SDS-PAGE was performed to assess the sample purity.

To obtain a pre-purified SARS-CoV-2 nsp7+8 complex for DLS and SAXS, eluate fractions from the Ni^{2+}-NTA column containing the nsp7-8-His$_6$ were concentrated and the buffer exchanged with a PD-10 desalting column (GE Healthcare) equilibrated with 50 mM Tris, pH 8.0, 100 mM NaCl, 4 mM DTT and 4 mM MgCl$_2$ (SEC-buffer). Then nsp7-8-His$_6$ was eluted with 3.5 mL SEC-buffer and subsequently cleaved with M^{Pro}-His$_6$ (1:5, M^{Pro}-His$_6$: nsp7-8-His$_6$) for 16 h at RT. M^{Pro}-His$_6$ was removed with Ni-NTA agarose and the cleaved nsp7+8 complex was subjected to a HiLoad 16/600 Superdex 75 pg size exclusion column equilibrated with SEC-buffer.

The HCoV-229E, PEDV, FIPV and TGEV nsp7-8-His$_6$ and MERS-CoV nsp7-11-His$_6$ precursor

proteins were produced and purified as described before (Tvarogová et al., 2019) with a

slightly modified storage buffer. Anion exchange chromatography fractions of the peak

containing the desired protein were identified by SDS-PAGE, pooled and dialyzed against

storage buffer (50 mM Tris-Cl, pH 8.0, 200 mM NaCl and 2 mM DTT).

MBP-nsp5-His$_6$ fusion proteins were purified using Ni^{2+}-IMAC as described before

(Tvarogová et al., 2019). To produce HCoV-229E and FIPV MBP-nsp5-His$_6$, *E. coli* TB1 cells

were transformed with the appropriate pMAL-c2-MBP-nsp5-His$_6$ construct and grown at

37 °C in LB medium containing ampicillin (100 µg/mL). When an OD$_{600}$ of 0.6 was reached,

protein production was induced with 0.3 mM isopropyl β-D-thiogalactopyranoside (IPTG)

and cells were grown for another 16 h at 18 °C. Thereafter, the cultures were centrifuged

(6000 × g for 20 min) and the cell pellet was suspended in lysis buffer (20 mM Tris-Cl, pH 8.0,

300 mM NaCl, 5 % glycerol, 0.05 % Tween-20, 10 mM imidazole and 10 mM β-

mercaptoethanol) and further incubated with lysozyme at 4 °C (0.1 mg/mL) for 30 min.

Subsequently, cells were lysed by sonication and cell debris was removed by centrifugation

for 30 min at 40,000 × g and 4°C. The cell-free extract was bound to pre-equilibrated Ni^{2+}-NTA

(Qiagen) matrix for 3 h. Ni^{2+}-IMAC elution fractions were dialyzed against buffer comprised

of 20 mM Tris-Cl, pH 7.4, 200 mM NaCl, 5 mM CaCl$_2$ and 2 mM DTT and cleaved with

factor Xa to release nsp5-His$_6$. Then, nsp5-His$_6$ was passed through an amylose column and

subsequently bound to Ni^{2+}-NTA matrix to remove any remaining MBP. Following elution

from the Ni^{2+}-NTA column, nsp5-His$_6$ was dialyzed against storage buffer (20 mM Tris-Cl,

pH 7.4, 200 mM NaCl and 2 mM DTT) and stored at -80 °C until further use.

Native mass spectrometry

To prepare samples for native MS measurements, M^{pro} was buffer exchanged into 300 mM

AmAc, 1 mM DTT, pH 8.0 by two cycles of centrifugal gel filtration (Biospin mini columns,

6,000 MWCO, BioRad) and the precursors were transferred into 300 mM AmAc, 1 mM DTT,

pH 8.0 by five rounds of dilution and concentration in centrifugal filter units (Amicon,

10,000 MWCO, Merck Millipore). Cleavage and complex formation was started by mixing

nsp7-8-His$_6$ and protease M^{pro} with final concentrations of 15 µM and 3 µM, respectively.

Three independent reactions were started in parallel and incubated at 4 °C overnight.

Tips for nano-electrospray ionization (nanoESI) were pulled in-house from borosilicate capillaries (1.2 mm outer diameter, 0.68 mm inner diameter, with filament, World Precision Instruments) with a micropipette puller (P-1000, Sutter Instruments) using a squared box filament (2.5 × 2.5 mm, Sutter Instruments) in a two-step program. Subsequently, tips were gold-coated using a sputter coater (Q150R, Quorum Technologies) with 40 mA, 200 s, tooling factor 2.3 and end bleed vacuum of 8×10^{-2} mbar argon.

Native MS was performed at a nanoESI quadrupole time-of-flight (Q-TOF) instrument (Q-TOF2, Micromass/Waters, MS Vision) modified for higher masses [34]. Samples were ionized in positive ion mode with voltages applied at the capillary of 1300-1500 V and at the cone of 130-135 V. The pressure in the source region was kept at 10 mbar throughout all native MS experiments. For desolvation and dissociation, the pressure in the collision cell was 1.5×10^{-2} mbar argon. For native MS, accelerating voltages were 10 - 30 V and quadrupole profile 1,000 - 10,000 m/z. For CID-MS/MS, acceleration voltages were 30 - 200 V. Raw data were calibrated with CsI (25 mg/mL) and analyzed using MassLynx 4.1 (Waters). Peak deconvolution and determination of relative intensity was performed using UniDec [35]. All determined masses are provided (Table S 1).

XL-MALDI

Pre-purified FIPV nsp7+8 and HCoV-229E nsp7+8 at 20 µM were cross-linked with 0.15 % glutaraldehyde (Sigma-Aldrich) at 4 °C for 25 min before diluting them to 1 µM in MALDI matrix solution (sinapinic acid 10 mg/mL in acetonitrile/water/TFA, 49.95/49.95/0.1, *v/v/v*) and spotting (1 µL) onto a stainless steel MALDI target plate. The MALDI-TOF/TOF mass spectrometer (ABI 4800, AB Sciex) equipped with a high-mass detector (HM2, CovalX) was used in linear mode. For acquiring mass spectra (1,000 to 1,000,000 m/z) spots were ionized with a Nd:YAG laser (355 nm) and 500 shots per spectrum were accumulated. Obtained raw data were smoothed and analyzed using mMass (v5.5.0, by Martin Strohalm [36]).

DLS

To check the monodispersity of the samples and to study the stoichiometry of the nsp7+8 complexes, DLS measurements were performed with the Spectro Light 600 (Xtal Concepts). The complex was concentrated to various concentrations and samples were spun down for 10 min at 12,000 rpm and 4 °C. A Douglas Vapour batch plate (Douglas instruments) was

567 filled with paraffin oil and 2 μL of each sample was pipetted under oil. DLS measurements

568 for each sample were performed at 20 °C with 20 measurements for 20 s each, respectively.

SAXS

SAXS data were collected on the P12 beamline of EMBL at the PETRA III storage ring (DESY,

Hamburg). X-ray wavelength of 1.24 Å (10 keV) was used for the measurements, scattered

photons were collected on a Pilatus 6M detector (Dectris), with a sample to detector distance

of 3 m. Data were collected on 22 concentrations ranging from 1.2 to 48 mg/mL nsp7+8 in

50 mM Tris, pH 8.0, 100 mM NaCl, 4 mM DTT and 4 mM $MgCl_2$, pure buffer was measured

between samples. For each data collection, 20 frames of 100 ms were collected. 2D scattering

images were radially averaged and normalized to the beam intensity. The frames were

compared using the program Cormap [37, 38], and only similar frames were averaged and

used for further analysis to avoid possible beam-induced effects. Scattering collected on the

pure buffer was subtracted from that of the sample and the resulting curves were normalized

to the protein concentration to obtain the scattering of nsp7+8 complexes.

The data processing pipeline SASflow was used for data reduction and calculation of the

overall SAXS parameters [38]. Molecular weights were inferred from different molecular

calculation methods using a Bayesian assessment [39]. The program CRYSOL was used to

compute the theoretical curves from the atomic structures [40]. Volume fractions of the

components of the oligomeric mixtures were computed and fitted to the data using the

program OLIGOMER [41]. The dimer of T1 was built by the program SASREFMX [42],

which builds a dimeric model that fits best, in mixture with the monomeric T1, multiple

scattering curves collected at different concentrations.

Visualization

590 Molecular graphics and analyses were performed with UCSF ChimeraX, developed by the

591 Resource for Biocomputing, Visualization, and Informatics at the University of California,

592 San Francisco, with support from National Institutes of Health R01-GM129325 and the Office

593 of Cyber Infrastructure and Computational Biology, National Institute of Allergy and

594 Infectious Diseases.

Acknowledgements

596 We would like to thank the XBI User consortium for providing the instrumentation and

597 laboratories at the European XFEL.

Author contributions

Conceptualization and methodology - B.K., C.S., C.U. G.B., R.M. and J.Z.; plasmid construction and protein production - B.K., C.S., G.B. , L.B.; providing research materials C.U., K.L. and J.Z.; XL-MALDI-MS - B.K., M.K. and R.Z.; SAXS: C.B., D.S. Investigation - B.K., G.B., C.S., R.S. Discussion of results - B.K., C.S., C.U., K.L., R.M., G.B., J.Z.; Formal analysis and visualization - B.K.; Original Draft - B.K. and C.U.; Writing, review and editing - B.K. and C.U. with help from all authors.

Funding

The Heinrich Pette Institute, Leibniz Institute for Experimental Virology is supported by the Free and Hanseatic City of Hamburg and the Federal Ministry of Health. C.U. and B.K. are supported by EU Horizon 2020 ERC StG-2017 759661. C.U. and B.K. also received funding through Leibniz Association SAW-2014-HPI-4 grant. B.K. acknowledges funding from COST BM1403.The work of J.Z., G.B. and R.M. was supported by grants (to J.Z.) from the Deutsche Forschungsgemeinschaft (SFB 1021, A01; IRTG 1384) and the LOEWE program of the state of Hessen (DRUID, B02).

615 **Table S 1: Mass table.** Data from at least three representative native mass spectra were analyzed with MassLynx
616 4.1 and UniDec. M_{theo} is calculated based on amino acid sequence. Full width half-maximum (FWHM) values
617 derived from main peaks, charge state given in parenthesis. Three data points are used for calculation of average
618 (Avg) and standard deviation (SD) (only two for PEDV complexes).

	Oligomer	M_{theo} (Da)	Avg M_{exp} ± SD (Da)	Avg FWHM (Da) and charge state	nsp7+8 relative intensity fraction (%)
SARS-CoV-2	nsp7+8 (1:1)	31121	31140 ± 10	62 (11+)	4 ± 2
	nsp7+8 (2:1)	-	-	-	-
	nsp7+8 (2:2)	62242	62300 ± 20	155 (15+)	96 ± 2
SARS-CoV	nsp7+8 (1:1)	31129	31123 ± 2	20 (11+)	2.3 ± 0.2
	nsp7+8 (2:1)	-	-	-	-
	nsp7+8 (2:2)	62258	62267 ± 2	65 (15+)	97.6 ± 0.2
MERS-CoV	nsp7+8 (1:1)	30931	30954.0 ± 0.0	20 (10+)	73 ± 11
	nsp7+8 (2:1)	40012	40025 ± 2	22 (11+)	8 ± 1
	nsp7+8 (2:2)	61898	61920 ± 10	75 (14+)	19 ± 11
PEDV	nsp7+8 (1:1)	30895	30927 ± 1	20 (10+)	52 ± 4
	nsp7+8 (2:1)	40102	40238 ± 3	27 (11+)	6 ± 1
	nsp7+8 (2:2)	61723	61863 ± 1	45 (15+)	42 ± 2
HCoV-229E	nsp7+8 (1:1)	30901	30920 ± 10	20 (10+)	20 ± 7
	nsp7+8 (2:1)	40188	40145 ± 1	29 (11+)	12 ± 1
	nsp7+8 (2:2)	61793	61839 ± 1	45 (15+)	69 ± 6
TGEV	nsp7+8 (1:1)	30930	30962 ± 6	22 (11+)	17 ± 3
	nsp7+8 (2:1)	40401	40470 ± 20	68 (12+)	83 ± 3
	nsp7+8 (2:2)	-	-	-	-
FIPV	nsp7+8 (1:1)	308334	30850 ± 5	26 (11+)	17 ± 2
	nsp7+8 (2:1)	40234	40400 ± 100	208 (12+)	83 ± 2
	nsp7+8 (2:2)	-	-	-	-

620 **Table S 2: Sequence identity matrix of nsp7-8 species.** Values for pairwise sequence identity are given in
621 percent. For the multiple sequence alignment with identity matrix output the SIAS Sequence identity and
622 similarity tool has been used provided by Secretaria general de sciencia, technologica e innovacion of Spain
623 (**http://imed.med.ucm.es/Tools/sias.html**). As input parameter, length of the smallest sequence was selected.

	SARS-CoV-2	SARS-CoV	HCoV-229E	PEDV	FIPV	TGEV	MERS
SARS-CoV-2	100						
SARS-CoV	98	100					
HCoV-229E	43	44	100				
PEDV	42	42	71	100			
FIPV	42	43	63	62	100		
TGEV	42	42	64	61	94	100	
MERS	28	28	21	21	20	20	100
%	SARS-CoV-2	SARS-CoV	HCoV-229E	PEDV	FIPV	TGEV	MERS

626 **Table S 3: SAXS experimental parameters and analysis methods.**

Data collection parameters	
Instrument	EMBL P12 (PETRAIII, DESY, Hamburg)
beam geometry (mm^2)	0.2 × 0.12
Wavelength (nm)	0.12
S-range (nm^{-1})	0.03 – 5
exposure time (s)	2 (20 × 0.1)
temperature (K)	293
Software employed	
primary data reduction	SASFLOW
data processing	PRIMUS
computation of model intensities	CRYOL
determination of mixture volume fraction	OLIGOMER
rigid body modelling	SASREFMX

627 **Table S 4: Overall parameters computed from the SAXS curves.**

c (mg/mL)	Rg (nm)	MW Bayes (kDa)	Fit to tetramer T1	Mixture of tetramer and dimer of tetramer		Mixture of tetramer and hexadecamer	
			x^2	x^2	Tetramer volume fraction	x^2	Tetramer volume fraction
1.2	3.25	46	1.35	1.34	1	1.34	1
1.2	3.41	58	1.27	1.27	1	1.27	1
2.1	3.37	56	1.31	1.41	0.97	1.47	1
3.9	3.46	60	2.57	2.54	0.9	3.7	0.98
4.4	3.41	62	1.97	2.2	0.9	3.34	0.97
7.7	3.56	62	5.13	2.3	0.8	4.84	0.95
9.1	3.67	67	14.32	2.45	0.69	9.54	0.91
10.4	3.79	62	22.95	4.4	0.73	15.02	0.93
10.6	3.79	74	21.79	2.86	0.66	12.75	0.91
11.5	3.66	62	4.94	2.14	0.79	4.77	0.94
12.8	3.73	74	62.98	5.13	0.63	30.59	0.9
13.1	3.53	62	19.63	5.29	0.77	15.77	0.94
16.6	3.82	74	17.89	2.27	0.64	9.96	0.9
20	3.67	68	40.19	5.59	0.68	20.25	0.91
21.1	3.82	74	67.56	4.62	0.61	29.52	0.89
25.8	3.8	74	73	4.69	0.57	27.08	0.88
26.6	3.86	74	58.68	6.49	0.62	24.02	0.89
31.1	3.91	83	148.76	7.82	0.52	45.67	0.86
32.1	3.82	76	111.04	10.92	0.61	41.36	0.89
47.7	3.95	86	86.73	6.57	0.47	21.69	0.84

629 **Table S 5: Results table, overview of main experimental results for nsp7+8 complexes of seven CoV species.**
630 Results from left to right: Categorization of complexes, quantitation of complexes by native MS (values are given
631 in percent), identified homodimers nsp7$_2$ and nsp8$_2$, and dimerization of precursor (clearly assigned species
632 indicated with "yes" and if no assignment possible with minus(-)), nsp8 and nsp7 possible mutations that shift
633 heterotrimer to heterotetramer formation.

	Group	Complex nsp7+8 (1:1)	Complex nsp7+8 (2:1)	Complex nsp7+8 (2:2)	Dimer nsp7 (2)	Dimer nsp8 (2)	Dimer nsp7-8	nsp8 Glu77/ Asn78	nsp7 Phe76
SARS-CoV-2	A	4	-	96	yes	yes	yes	Glu77	-
SARS-CoV	A	2	-	98	yes	yes	yes	Glu77	-
MERS-CoV	AB	73	8	19	yes	-	*different precursor	Glu77	Phe76
HCoV-229E	AB	20	12	69	yes	-	yes	Asn78	Phe76
PEDV	AB	52	6	42	yes	-	yes	Asn78	Phe76
FIPV	B	17	83	-	yes	-	-	-	Phe76
TGEV	B	17	83	-	yes	-	-	-	Phe76

636 **Table S 6: Amino acid sequences of precursor constructs.**

>SARS-CoV-2_nsp7-8-His$_6$
SKMSDVKCTSVVLLSVLQQLRVESSSKLWAQCVQLHNDILLAKDTTEAFEKMVSLLSVLLSMQGAVDINKLCEEMLDNRATLQAI ASEFSSLPSYAAFATAQEAYEQAVANGDSEVVLKKLKKSLNVAKSEFDRDAAMQRKLEKMADQAMTQMYKQARSEDKRAKVTS AMQTMLFTMLRKLDNDALNNIINNARDGCVPLNIIPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEIS MDNSPNLAWPLIVTALRANSAVKLQ**SGSGSARGSHHHHHH**

>SARS-CoV_nsp7-8-His$_6$
SKMSDVKCTSVVLLSVLQQLRVESSSKLWAQCVQLHNDILLAKDTTEAFEKMVSLLSVLLSMQGAVDINRLCEEMLDNRATLQAI ASEFSSLPSYAAYATAQEAYEQAVANGDSEVVLKKLKKSLNVAKSEFDRDAAMQRKLEKMADQAMTQMYKQARSEDKRAKVTS AMQTMLFTMLRKLDNDALNNIINNARDGCVPLNIIPLTTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEI NMDNSPNLAWPLIVTALRANSAVKLQ**SARGSHHHHHH**

>HCoV-229E_nsp7-8-His$_6$
SKLTDLKCTNVVLMGILSNMNIASNSKEWAYCVEMHNKINLCDDPETAQELLLALLAFFLSKHSDFGLGDLVDSYFENDSILQSVA SSFVGMPSFVAYETARQEYENAVANGSSPQIIKQLKKAMNVAKAEFDRESSVQKKINRMAEQAAAAMYKEARAVNRKSKVVSA MHSLLFGMLRRLDMSSVDTILNMARNGVVPLSVIPATSAARLVVVVPDHDSFVKMMVDGFVHYAGVVWTLQEVKDNDGKNVHL KDVTKENQEILVWPLILTCERVVKLQ**SGSGHHHHHH**

>PEDV_nsp7-8-His$_6$
SKLTDIKCSNVVLLGCLSSMNVSANSTEWAYCVDLHNKINLCNDPEKAQEMLLALLAFFLSKNSAFGLDDLLESYFNDNSMLQSV ASTYVGLPSYVIYENARQQYEDAVNNGSPPQLVKQLRHAMNVAKSEFDREASTQRKLDRMAEQAAAQMYKEARAVNRKSKVV SAMHSLLFGMLRRLDMSSVDTILNLAKDGVVPLSVIPAVSATKLNIVTSDIDSYNRIQREGCVHYAGTIWNIIDIKDNDGKVVHVKEV TAQNAESLSWPLVLGCERIVKLQ**SGSGHHHHHH**

>FIPV_nsp7-8-His$_6$
SKLTEMKCTNVVLLGLLSKMHVESNSKEWNYCVGLHNEINLCDDPDAVLEKLLALIAFFLSKHNTCDLSDLIESYFENTTILQSVAS AYAALPSWIAYEKARADLEEAKKNDVSPQLLKQLTKACNIAKSEFEREASVQKKLDKMAEQAAASMYKEARAVDRKSKIVSAMHS LLFGMLKKLDMSSVNTIIEQARNGVLPLSIIPAASATRLIVVTPNLEVLSKVRQENNVHYAGAIWSIVEVKDANGAQVHLKEVTAAN ELNITWPLSITCERTTKLQ**SGSGHHHHHH**

>TGEV_nsp7-8-His$_6$
SKLTEMKCTNVVLLGLLSKMHVESNSKEWNYCVGLHNEINLCDDPEIVLEKLLALIAFFLSKHNTCDLSELIESYFENTTILQSVASA YAALPSWIALEKARADLEEAKKNDVSPQILKQLTKAFNIAKSDFEREASVQKKLDKMAEQAAASMYKEARAVDRKSKIVSAMHSLL FGMLKKLDMSSVNTIIDQARNGVLPLSIIPAASATRLVVITPSLEVFSKIRQENNVHYAGAIWTIVEVKDANGSHVHLKEVTAANELN LTWPLSITCERTTKLQ**SGSGHHHHHH**

>MERS-CoV_nsp7-11-His$_6$
SKLTDLKCTSVVLLSVLQQLHLEANSRAWAFCVKCHNDILAATDPSEAFEKFVSLFATLMTFSGNVDLDALASDIFDTPSVLQATL SEFSHLATFAELEAAQKAYQEAMDSGDTSPQVLKALQKAVNIAKNAYEKDKAVARKLERMADQAMTSMYKQARAEDKKAKIVSA MQTMLFGMIKKLDNDVLNGIISNARNGCIPLSVIPLCASNKLRVVIPDFTVWNQVVTYPSLNYAGALWDITVINNVDNEIVKSSDVV DSNENLTWPLVLECTRASTSAVKLQNNEIKPSGLKTMVVSAGQEQTNCNTSSLAYYEPVQGRKMLMALLSDNAYLKWARVEGK DGFVSVELQPPCKFLIAGPKGPEIRYLYFVKNLNNLHRGQVLGHIAATVRLQAGSNTEFASNSSVLSLVNFTVDPQKAYLDFVNAG GAPLTNCVKMLTPKTGTGIAISVKPESTADQETYGGASVCLYCRAHIEHPDVSGVCKYKGKFVQIPAQCVRDPVGFCLSNTPCNV CQYWIGYGCNCDSLRQAALPQ**SKDSNFLNHHHHHH**

Figure S 1: Mpro mediated processing of precursor protein constructs. SDS-PAGE analysis of M[Pro] (nsp5)-mediated processing and generation of coronavirus nsp7+8 complexes with authentic *N-* and *C-*termini from polyprotein precursors nsp7-8, nsp7-8-9 and nsp7-11. The nsp7+8 complexes of HCoV-229E, PEDV, FIPV, TGEV, and SARS-CoV were produced from the respective nsp7-8-His6 precursors and MERS-CoV was produced from an nsp7-9-His6 precursor. Precursor proteins were purified by Ni^{2+}-IMAC and ion-exchange chromatography. Then, 15 µg protein was cleaved with M[Pro] (nsp5-His6, 5 µg) for 48 h at 4 °C. Subsequently, His6-tag containing cleavage products were removed by passing the material through a Ni^{2+}-IMAC column and nsp7+8 complexes were enriched by ion-exchange chromatography. (**A**) SDS-PAGE showing the purified M[Pro] (nsp5-His6) – lanes 1, 5, 9, 13, 17; nsp7-8- His6 – lanes 2, 6, 10, 14, 18; M[Pro]-mediated cleavage reaction – lanes 3, 7, 11, 15, 19; enriched nsp7+8 complexes – lanes 4, 8, 12, 16, 20. (**B**) SDS-PAGE showing the purified M[Pro] (nsp5-His6) – lane 1; nsp7-8-9-His6 – lane 2; M[Pro]-mediated cleavage reaction – lane 3; enriched nsp7+8 complex – lane 4. (**C**) SDS-PAGE showing the purified M[Pro] (nsp5-His6) – lane 1; nsp7-8-9-10-11-His6 – lane 2; M[Pro] mediated cleavage reaction – lane 3. Lane M, marker proteins with molecular masses in kD indicated to the left. Black arrows on the right indicate the identities of proteins generated from precursor proteins by M[Pro]-mediated cleavage. Gray arrowheads indicate aberrant *in vitro* cleavage products of nsp8 as observed previously for SARS-CoV [22]. nsp – nonstructural protein. +/– indicate the presence or absence of the respective proteins.

Figure S 2: Native MS of nsp7+8 complexes of seven CoVs representing five different CoV species.
Representative mass spectra showing distinct nsp7+8 complexation patterns that were classified into the three
groups A, B and AB. Complex formation triggered by M^{pro} (M) mediated cleavage of 15 µM nsp7-8-His$_6$ or MERS-
CoV nsp7-11-His$_6$ precursors in 300 mM AmAc, 1 mM DTT, pH 8.0. (**A**) SARS-CoV and (**B**) SARS-CoV-2 from
group A forming nsp7+8 (2:2) heterotetramers (red), (**C**) FIPV and (**D**) TGEV from group B forming nsp7+8 (2:1)
heterotrimers (blue) as well as (**E**) HCoV-229E and (**F**) PEDV from group AB forming both complex
stoichiometries. (**G**) MERS-CoV, also from group AB, produced from an nsp7-11 precursor, additionally results in
several processing intermediates that allow for an estimation of relative cleavage efficiencies at different cleavage
sites. All groups form nsp7+8 (1:1) heterodimers as intermediate state (green).

Figure S 3: Zoom in on nsp7 and nsp8 monomers and homodimers from spectra in Figure S 2. Representative
native mass spectra showing region 1500-3600 *m/z* (for full spectra see Figure S 2) of cleaved nsp7-8 or nsp7-11
precursors showing that homodimers of nsp8 (green, nsp8₂) were detected for SARS-CoV (**A**) and SARS-CoV-2
(**B**), but not for (**C**) FIPV, (**D**) TGEV, (**E**) HCoV-229E, (**F**) PEDV and (**G**) MERS-CoV. Homodimers of nsp7 (yellow,
nsp7₂) were detected for all seven CoVs.

Figure S 4: Mass and oligomeric state of nsp7-8 precursors. Native MS of nsp7-8 precursors (**A-G**) sprayed at 18 μM from 300 mM AmAc, pH 8.0 and 1 mM DTT. Dominant charge envelope is highlighted (blue box). Labelled are charge states and molecular mass. (**C**) Inset shows mass heterogeneity in FIPV nsp7-8. The experimental molecular weight M_{exp} of the precursors agrees with the sequence-derived theoretical M_{theo} (Table S 1). Only FIPV nsp7-8 contained two mass species separated by ~110 Da. This heterogeneity was attributed to the precursor's central nsp8 domain following M^{pro} processing. Assignment to an amino acid

681 variation failed but potentially was the result of codon heterogeneity in the plasmid. Nevertheless, both forms
682 behaved identical and we refrained from further optimization.

Figure S 5: Monomer-dimer equilibrium in SARS-CoV and SARS-CoV nsp7-8 precursors. Native mass spectra of nsp7-8 precursors of SARS-CoV (**A**) 18 μM and (**B**) 9 μM and SARS-CoV-2 (**C**) 18 μM and (**D**) 9 μM. Proteins at 18 μM were diluted to 9 μM, incubated for 10 min and then sprayed from 300 mM AmAc, pH 8.0 and 1 mM DTT. Charge states are labelled.

Figure S 6: Topological reconstruction from CID-MS/MS of TGEV and FIPV nsp7+8 heterotrimers. (**A**) Three product ion spectra of TGEV 11+ nsp7+8 (2:1) heterotrimers are shown at different collisional voltages (CV). Increased collisional activation allows assignment of additional charge states and product species. (**B**) Product ion spectra of the FIPV 11+ nsp7+8 (2:1) show a similar dissociation pattern as its homologue from TGEV. (**C**) Schematic pathway of dissociation allows for a topological reconstruction of the TGEV and FIPV heterotrimers.

Figure S 7: Topological reconstruction from CID-MS/MS of PEDV and HCoV-229E nsp7+8 heterotrimers. (**A**) Product ion spectra of PEDV 11+ nsp7+8 (2:1) heterotrimers shows nsp7 homodimeric species, revealing the core interaction of this protein complex. (**B**) Product ion spectra of HCoV-229E 11+ nsp7+8 (2:1) heterotrimers are shown. Compared to the dissociation pattern of PEDV homologue, the HCoV-229E nsp7 and nsp8 high charge products have distinct intensities and charge state distributions but the detected product species are similar. (**C**) Schematic pathway of dissociation allows for a topological reconstruction of the PEDV and HCoV-229E heterotrimer.

Figure S 8: Topological reconstruction from CID-MS/MS of PEDV and HCoV-229E nsp7+8 heterotetramers.
(**A**) Product ion spectra of PEDV 16+ nsp7+8 (2:2) heterotetramers are shown at two different CV. At 80 V CV, the dissociation of one nsp7 or alternatively one nsp8 occurs, as indicated by the high and low charge products. Notably, the high charge state of the dissociated nsp8 suggests an extended shape of the ion. At 140 V CV, nsp8 dissociates at lower charge states suggesting alternative dissociation pathways. (**B**) Product ion spectra of HCoV-229E 16+ nsp7+8 (2:2) heterotetramers at 140 V are similar to the PEDV heterotetramers. (**C** and **D**) The zoom (2000-9000 *m/z*), excluding the nsp8 high charge states, reveals additional product species (e.g. the nsp8₂ homodimer). (**E**) Schematic pathway of dissociation allows for a topological reconstruction of the PEDV and HCoV-229E heterotetramer.

Figure S 9: Topological reconstruction from CID-MS/MS of MERS-CoV nsp7+8 heterotetramers. (**A**) Product ion spectra of MERS-CoV 15+ nsp7+8 (2:2) heterotetramers are shown at two different CV. At 100 V CV, the dissociation of one nsp7 or, alternatively, one nsp8 occurs as indicated by the high and low charge products. At 140 V CV, other dissociation products increase in intensity (e.g. nsp8$_2$ homodimer and nsp7+8(1:1) heterodimer). (**B**) Schematic pathway of dissociation allows topological reconstruction of the MERS-CoV heterotetramers.

720 **Figure S 10: Topological reconstruction from CID-MS/MS of SARS-CoV and SARS-CoV-2 nsp7+8**
721 **heterotetramers.** Product ion spectra of (**A**) SARS-CoV-2 and (**B**) SARS-CoV 17+ nsp7+8 (2:2) heterotetramers are
722 shown. High charge state precursor allows for efficient dissociation already at relatively low activation (CV 80 V).
723 Product ion species can be clearly assigned from the overview spectra. (**C**) Schematic pathway of dissociation
724 allows topological reconstruction of the SARS-CoV-2 and SARS-CoV heterotetramers.

Figure S 11: MALDI-MS of nsp7+8 complexes from FIPV and HCoV-229E stabilized with crosslinker. (**A**) MALDI mass spectrum of FIPV nsp7+8 crosslinked with 0.15 % glutaraldehyde for 25 min at 4 °C. Inset shows the most abundant nsp7+8 complexes: (1:1) heterodimer (32.4 kDa) and (2:1) heterotrimer (42.5 kDa). Abundance is determined from relative peak areas as indicated (red). (**B**) MALDI mass spectrum of HCoV-229E nsp7+8 crosslinked with 0.15 % glutaraldehyde for 25 min at 4 °C. Inset shows most abundant nsp7+8 complexes: (1:1) heterodimer (32.2 kDa) and (2:2) heterotetramer (64.6 kDa). Abundance is determined from relative peak areas as indicated (blue). Symbols depict stoichiometry of mass species of nsp7 (yellow) and nsp8 (green) with highest signal strength. Masses are higher in crosslinked samples due to the additional glutaraldehyde molecules. Mass spectra were not calibrated. Each spectrum shown was generated from three MALDI spots. Most signals, except for the HCoV-229E heterotetramer, above 50,000 *m/z* are low abundant and likely due to over-crosslinking.

Figure S 12: SDS-PAGE analysis of chemically cross-linked HCoV-229E, FIPV, and SARS-CoV nsp7+8 complexes. The 5 μg protein of nsp7+8 complexes were crosslinked with 10 μM BS[3] (ThermoFisher) in reaction buffer (20 mM HEPES-KOH, pH 8.0, 30 mM KCl, and 2 mM β-mercaptoethanol). Crosslinking was carried out at 37 °C for 30 min and quenched with 50 mM AmAc for another 30 min at 37 °C. After terminating the crosslinking reaction, the samples were mixed with an excess of Laemmli sample buffer (50 mM Tris-HCl, pH 6.8, 2.5 % (*w/v*) SDS, 10 % (*v/v*) glycerol, and 0.01 % (*w/v*) bromophenol blue) and analyzed on 12 % SDS-PAGE. Lanes 1, 3, 5 – nsp7+8 complexes not treated with BS[3] (-) and lanes 2, 4, 6 – nsp7+8 complexes treated with BS[3]. Lane M, marker proteins; molecular masses in kD are indicated to the left. Black arrows on the right indicate the different oligomeric states of the nsp7+8 complexes obtained by crosslinking.

Figure S 13: Candidate structures in agreement with the observed stoichiometries and topologies observed. (**A**)
For the full-length heterotetramer, an isolated structure does not exist. However from the larger SARS-CoV
nsp7+8 hexadecamer [20] (pdb 2ahm), two conformer subcomplexes of nsp7+8 (2:2), T1 and T2, can be extracted.
Both conformers constitute a head-to-tail interaction of two heterodimers by an nsp8:nsp8 interface. Notably,
nsp8 in T1 is more extended, containing an almost full-length amino acid sequence (2-193), while in T2 the nsp8
N-terminal 35 to 55 residues are unresolved. (**B**) For the trimeric complexes, the only deposited structure is
FIPV nsp7+8 (2:1) trimer [21] (pdb 3ub0), which agrees well with our experimental topology.

Figure S 14: Fits to all SAXS data. Experimental data (blue with experimental errors) for SARS-CoV-2 nsp7+8 complexes fitted with a mixture of T1 and hexadecamer (red), or T1 and dimer of T1 (green).

Figure S 15: Sequence alignment of nsp7 and nsp8 from seven CoV species. The multiple sequence alignment of nsp7-8 sequences of the seven tested CoVs is genrated with Clustal Omega [43] and converted by ESPript [44] - http://espript.ibcp.fr using the amino acid sequences without C-terminal linkers and His₆ as input (Table S 6). Highlighted are conserved (black) and semi-conserved (bold) sequences. Further highlighted are molecular contacts at binding site (BS) II in the SARS-CoV nsp7+8 (2:2) heterotetramer candidate structures T1 (green) and T2 (orange) (subcomplexes of pdb 2ahm) as well as in the FIPV nsp7+8 (2:2) heterotrimer (pink, pdb 3ub0). Contacts (VDW radius -0.4 Å) was analyzed with ChimeraX [45].

Figure S 16: Conserved stretch of nsp8 has various binding contexts. Candidate complexes involving similar conserved residues (red) in the nsp8 BS II are shown here for (**A**) the SARS-CoV nsp7+8 (2:2) heterotetramer candidate structures T1 and (**B**) T2 (subcomplexes of pdb 2ahm) as well as (**C**) the FIPV nsp7+8 (2:2) heterotrimer (pdb 3ub0). (**D**) Cryo electron microscopy structure of the nsp7+8+12+13 (1:2:1:1) polymerase complex (pdb 6xez) [29]. The two subunits of nsp8 (green), bind as a monomer nsp8a and as a nsp7+nsp8b heterodimer to the nsp12 RdRp. From there, nsp8a and nsp8b extend and interact as a facet with the RNA duplex and also individually with one subunit of the nsp13 helicase. The molecular contacts between nsp8 and nsp12/13 are mediated by exactly the same amino acids in the nsp8 BS II that are involved in nsp7+8 complex formation. (**E**) Zoom into the interacting region at nsp8a and nsp8b BS II and its amino acids in contact (VDW radius -0.4 Å) with the nsp12 thumb domain (brown), nsp13.1 and nsp13.2 (blue). All side chains of residues involved in contacts are displayed. Molecular graphics and analyses performed with UCSF ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from National Institutes of Health R01-GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases [45].

1. References

1. Cui, J., F. Li, and Z.-L. Shi, *Origin and evolution of pathogenic coronaviruses.* Nature Reviews Microbiology, 2019. **17**(3): p. 181-192.
2. Zaki, A.M., et al., *Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.* New England Journal of Medicine, 2012. **367**(19): p. 1814-1820.
3. Drosten, C., et al., *Identification of a novel coronavirus in patients with severe acute respiratory syndrome.* New England Journal of Medicine, 2003. **348**(20): p. 1967-1976.
4. Novel, C.P.E.R.E., *The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China.* Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi, 2020. **41**(2): p. 145.

5. Gorbalenya, A.E., *Severe acute respiratory syndrome-related coronavirus–The species and*
its viruses, a statement of the Coronavirus Study Group. bioRxiv, 2020.
6. Dong, E., H. Du, and L. Gardner, *An interactive web-based dashboard to track COVID-19*
in real time. The Lancet infectious diseases, 2020. **20**(5): p. 533-534.
7. Pedersen, N.C., *An update on feline infectious peritonitis: virology and*
immunopathogenesis. The Veterinary Journal, 2014. **201**(2): p. 123-132.
8. Vlasova, A., et al., *Porcine coronaviruses*, in *Emerging and Transboundary Animal Viruses.*
2020, Springer. p. 79-110.
9. Snijder, E.J., E. Decroly, and J. Ziebuhr, *The Nonstructural Proteins Directing*
Coronavirus RNA Synthesis and Processing. Adv Virus Res, 2016. **96**: p. 59-126.
10. van Hemert, M.J., et al., *SARS-coronavirus replication/transcription complexes are*
membrane-protected and need a host factor for activity in vitro. PLoS Pathog, 2008. **4**(5): p.
e1000054.
11. Shannon, A., et al., *Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA*
polymerase. bioRxiv, 2020.
12. Subissi, L., et al., *One severe acute respiratory syndrome coronavirus protein complex*
integrates processive RNA polymerase and exonuclease activities. Proceedings of the
National Academy of Sciences of the United States of America, 2014. **111**(37): p.
E3900-E3909.
13. Kirchdoerfer, R.N. and A.B. Ward, *Structure of the SARS-CoV nsp12 polymerase bound to*
nsp7 and nsp8 co-factors. Nat Commun, 2019. **10**(1): p. 2342.
14. Gao, Y., et al., *Structure of the RNA-dependent RNA polymerase from COVID-19 virus.*
Science, 2020. **368**(6492): p. 779-782.
15. Peng, Q., et al., *Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core*
Polymerase Complex from SARS-CoV-2. Cell Reports, 2020. **31**(11): p. 107774.
16. Hillen, H.S., et al., *Structure of replicating SARS-CoV-2 polymerase.* bioRxiv, 2020.
17. Ferron, F., et al., *Structural and molecular basis of mismatch correction and ribavirin*
excision from coronavirus RNA. Proceedings of the National Academy of Sciences, 2018.
115(2): p. E162-E171.
18. Gordon, C.J., et al., *The antiviral compound remdesivir potently inhibits RNA-dependent*
RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem, 2020.
295(15): p. 4773-4779.
19. Krichel, B., et al., *Processing of the SARS-CoV pp1a/ab nsp7-10 region.* Biochem J, 2020.
20. Zhai, Y., et al., *Insights into SARS-CoV transcription and replication from the structure of*
the nsp7-nsp8 hexadecamer. Nat Struct Mol Biol, 2005. **12**(11): p. 980-6.
21. Xiao, Y., et al., *Nonstructural proteins 7 and 8 of feline coronavirus form a 2:1 heterotrimer*
that exhibits primer-independent RNA polymerase activity. J Virol, 2012. **86**(8): p. 4444-54.
22. Li, S., et al., *New nsp8 isoform suggests mechanism for tuning viral RNA synthesis.* Protein
Cell, 2010. **1**(2): p. 198-204.
23. Konkolova, E., et al., *Structural analysis of the putative SARS-CoV-2 primase complex.*
Journal of Structural Biology, 2020. **211**(2): p. 107548.
24. Dülfer, J., et al., *Structural mass spectrometry goes viral.* Advances in virus research,
2019. **105**: p. 189-238.
25. Erba, E., L. Signor, and C. Petosa, *Exploring the structure and dynamics of*
macromolecular complexes by native mass spectrometry. Journal of Proteomics, 2020: p.
103799.

26. Wang, G., A.J. Johnson, and I.A. Kaltashov, *Evaluation of electrospray ionization mass*
spectrometry as a tool for characterization of small soluble protein aggregates. Analytical
chemistry, 2012. **84**(3): p. 1718-1724.

27. Ziebuhr, J., *The coronavirus replicase*, in *Coronavirus replication and reverse genetics.* 2005,
Springer. p. 57-94.

28. Hegyi, A. and J. Ziebuhr, *Conservation of substrate specificities among coronavirus main*
proteases. J Gen Virol, 2002. **83**(Pt 3): p. 595-9.

29. Chen, J., et al., *Structural basis for helicase-polymerase coupling in the SARS-CoV-2*
replication-transcription complex. Cell, 2020.

30. Akabayov, B., et al., *Impact of macromolecular crowding on DNA replication.* Nature
communications, 2013. **4**(1): p. 1-10.

31. Von Brunn, A., et al., *Analysis of intraviral protein-protein interactions of the SARS*
coronavirus ORFeome. PloS one, 2007. **2**(5): p. e459.

32. Falke, S., *(Doctoral Thesis) Coronaviral Polyprotein Nsp7-10 : Proteolytic Processing and*
Dynamic Interactions within the Transcriptase/Replicase Complex. 2014, Staats- und
Universitätsbibliothek Hamburg.

33. Xue, X., et al., *Production of authentic SARS-CoV M pro with enhanced activity: application*
as a novel tag-cleavage endopeptidase for protein overproduction. Journal of molecular
biology, 2007. **366**(3): p. 965-975.

34. van den Heuvel, R.H., et al., *Improving the performance of a quadrupole time-of-flight*
instrument for macromolecular mass spectrometry. Anal Chem, 2006. **78**(21): p. 7473-83.

35. Marty, M.T., et al., *Bayesian deconvolution of mass and ion mobility spectra: from binary*
interactions to polydisperse ensembles. Analytical chemistry, 2015. **87**(8): p. 4370-4376.

36. Strohalm, M., et al., *mMass data miner: an open source alternative for mass spectrometric*
data analysis. Rapid Communications in Mass Spectrometry: An International Journal
Devoted to the Rapid Dissemination of Up-to-the-Minute Research in Mass
Spectrometry, 2008. **22**(6): p. 905-908.

37. Franke, D., C.M. Jeffries, and D.I. Svergun, *Correlation Map, a goodness-of-fit test for one-*
dimensional X-ray scattering spectra. Nature methods, 2015. **12**(5): p. 419.

38. Franke, D., A.G. Kikhney, and D.I. Svergun, *Automated acquisition and analysis of small*
angle X-ray scattering data. Nuclear Instruments and Methods in Physics Research
Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2012.
689: p. 52-59.

39. Hajizadeh, N.R., et al., *Consensus Bayesian assessment of protein molecular mass from*
solution X-ray scattering data. Scientific reports, 2018. **8**(1): p. 1-13.

40. Svergun, D., C. Barberato, and M.H. Koch, *CRYSOL–a program to evaluate X-ray*
solution scattering of biological macromolecules from atomic coordinates. Journal of applied
crystallography, 1995. **28**(6): p. 768-773.

41. Konarev, P.V., et al., *PRIMUS: a Windows PC-based system for small-angle scattering data*
analysis. Journal of applied crystallography, 2003. **36**(5): p. 1277-1282.

42. Petoukhov, M.V., et al., *New developments in the ATSAS program package for small-angle*
scattering data analysis. Journal of applied crystallography, 2012. **45**(2): p. 342-350.

43. Sievers, F., et al., *Fast, scalable generation of high-quality protein multiple sequence*
alignments using Clustal Omega. Molecular systems biology, 2011. **7**(1): p. 539.

44. Robert, X. and P. Gouet, *Deciphering key features in protein structures with the new*
ENDscript server. Nucleic acids research, 2014. **42**(W1): p. W320-W324.

45.   Goddard, T.D., et al., *UCSF ChimeraX: Meeting modern challenges in visualization and*
analysis. Protein Science, 2018. **27**(1): p. 14-25.